Pharmacopeia announced that the results from its s Phase 2a clinical trial evaluating PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), will be presented as a late-breaking clinical trial at the 23rd Annual Scientific Meeting and Exposition of the American Society of Hypertension (ASH) in New Orleans. PS433540 is being developed as a potential treatment for both hypertension and diabetic nephropathy, and is the first and only blood pressure product candidate in development that possesses two validated mechanisms of action in a single compound.